



www.genfit.com

GENFIT: IMPORTANT MEETING WITH INVESTIGATORS OF THE GFT505-212-7 STUDY DURING THE AMSTERDAM CONGRESS

- **GENFIT will participate in the 48th Annual meeting of the European Association for the Study of the Liver (EASL) being held from 24 to 28 April in Amsterdam**
- **GENFIT organizes a satellite meeting gathering together over 90 investigators of the GFT505-212-7 study from 60 expert centers involved in the recruitment of patients suffering from NASH, in the United States and 8 European countries.**

Lille (France), Boston (Massachusetts, United States), April 17, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its participation in the 48th Annual Congress of EASL, taking place in Amsterdam from April 24 to April 28, 2013.

This international liver congress is, along with the one organized by the AASLD (American Association for the Study of Liver Diseases), one of the most important annual meetings in the field of liver diseases. It brings together approximately 10 000 scientific and medical experts in the field (gastroenterologists & hepatologists). During this congress a large number of conferences provide new results on NASH, including its epidemiology, pathophysiology of disease progression, and clinical disease management. A number of these touch upon future treatments of NASH that are in development, including the potential of GFT505.

As a reminder, GENFIT has in progress one of the largest interventional studies ever conducted in the field of NASH, GFT505-212-7. A total of 75 to 80 expert centers in the United States and several European countries (France, Belgium, Netherlands, Italy, United Kingdom, Germany, Spain, Romania) are participating in this study and will recruit a total of 270 patients.

Jean-François Mouney, Chairman and CEO of GENFIT, declared: *'The GFT505-212-7 study is advancing very rapidly and over half of the required patients have already provided their consent to participate. Some of them have been under treatment for over 6 months, without any notable undesirable effects detected. The EASL congress is therefore ideally placed for organizing a satellite meeting which brings together a very large number of American and European investigators mobilized for this study. We will focus on the progression of the study and exchange on the latest scientific results of GFT505. This meeting will provide me an occasion to personally express all our satisfaction concerning everyone's extreme motivation to advance this study, a motivation that is reinforced by the urgent need of an efficient and safe drug for NASH. The sustained rhythm of patient recruitment allows us to serenely foresee publication of the final results at the end of 2014, following an important intermediate safety data review during the autumn of 2013.'*

***About NAFLD/NASH:**

NAFLD (non-alcoholic fatty liver disease) and in particular NASH (non-alcoholic steatohepatitis) are serious liver diseases that can lead to cirrhosis and liver cancer. The development of NAFLD/NASH is associated with the pathophysiological process of insulin resistance in patients that are overweight and/or diabetic. NAFLD is believed to affect 70-80% of diabetic patients, and progresses to chronic liver disease (NASH) in 20-50% of cases. Mortality due to liver disease is thus 2-3-fold higher in the diabetic population than in the overall population. The NASH market was estimated at 615 \$M in 2010 and should reach 2,008 \$M in 2018.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr